JPH08500110A - ブプロピオン含有持続放出型錠剤 - Google Patents

ブプロピオン含有持続放出型錠剤

Info

Publication number
JPH08500110A
JPH08500110A JP6506019A JP50601994A JPH08500110A JP H08500110 A JPH08500110 A JP H08500110A JP 6506019 A JP6506019 A JP 6506019A JP 50601994 A JP50601994 A JP 50601994A JP H08500110 A JPH08500110 A JP H08500110A
Authority
JP
Japan
Prior art keywords
hydrochloride
bupropion hydrochloride
release tablet
bupropion
tablet according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP6506019A
Other languages
English (en)
Japanese (ja)
Inventor
スー ギャロウエイ ラドウィグ，ジェニー
エルモア，ジュニア サットン，ジョエル
ルロイ，ジュニア バス，ウィリアム
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wellcome Foundation Ltd
Original Assignee
Wellcome Foundation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10720358&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JPH08500110(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wellcome Foundation Ltd filed Critical Wellcome Foundation Ltd
Publication of JPH08500110A publication Critical patent/JPH08500110A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • General Preparation And Processing Of Foods (AREA)
JP6506019A 1992-08-14 1993-08-13 ブプロピオン含有持続放出型錠剤 Pending JPH08500110A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB929217295A GB9217295D0 (en) 1992-08-14 1992-08-14 Controlled released tablets
GB9217295.6 1992-08-14
PCT/GB1993/001722 WO1994004138A1 (en) 1992-08-14 1993-08-13 Sustained release tablets containing bupropion

Publications (1)

Publication Number Publication Date
JPH08500110A true JPH08500110A (ja) 1996-01-09

Family

ID=10720358

Family Applications (1)

Application Number Title Priority Date Filing Date
JP6506019A Pending JPH08500110A (ja) 1992-08-14 1993-08-13 ブプロピオン含有持続放出型錠剤

Country Status (20)

Country Link
US (1) US5427798A (OSRAM)
EP (1) EP0656775B1 (OSRAM)
JP (1) JPH08500110A (OSRAM)
KR (1) KR100294154B1 (OSRAM)
AT (1) ATE161422T1 (OSRAM)
AU (1) AU677595B2 (OSRAM)
CA (1) CA2142320C (OSRAM)
CY (1) CY2143B1 (OSRAM)
DE (1) DE69316015T2 (OSRAM)
ES (1) ES2111168T3 (OSRAM)
GB (1) GB9217295D0 (OSRAM)
GR (1) GR3025794T3 (OSRAM)
IL (1) IL106693A (OSRAM)
LU (1) LU90656I2 (OSRAM)
MX (1) MX9304967A (OSRAM)
NZ (1) NZ254947A (OSRAM)
SG (1) SG43911A1 (OSRAM)
TW (1) TW260607B (OSRAM)
WO (1) WO1994004138A1 (OSRAM)
ZA (1) ZA935942B (OSRAM)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001517625A (ja) * 1997-09-25 2001-10-09 バイエル・アクチエンゲゼルシヤフト 活性成分放出制御薬物製剤
JP2002537319A (ja) * 1999-02-26 2002-11-05 アンドルックス ファーマスーティカルズ インコーポレーテッド 放出制御されたブプロピオン製剤
JP2023516404A (ja) * 2020-03-05 2023-04-19 アッヴィ・インコーポレイテッド エラゴリクスの投与方法

Families Citing this family (226)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9315856D0 (en) * 1993-07-30 1993-09-15 Wellcome Found Stabilized pharmaceutical
US5541231A (en) * 1993-07-30 1996-07-30 Glaxo Wellcome Inc. Stabilized Pharmaceutical
US5616344A (en) * 1994-06-14 1997-04-01 Fuisz Technologies Ltd. Apparatus and process for strengthening low density compression dosage units and product therefrom
US6221917B1 (en) 1997-12-30 2001-04-24 American Home Products Corporation Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
US5968553A (en) * 1997-12-30 1999-10-19 American Home Products Corporation Pharmaceutical composition containing bupropion hydrochloride and an inorganic acid stabilizer
US7098206B2 (en) * 1998-01-21 2006-08-29 Smithkline Beecham Corporation Pharmaceutically active morpholinol
US6998400B2 (en) * 1998-01-22 2006-02-14 Smithkline Beecham Corporation Pharmaceutically active morpholinol
CA2318921A1 (en) * 1998-01-29 1999-08-05 John R. Mccullough Pharmacological uses of optically pure (+)-bupropion
WO1999038499A2 (en) * 1998-01-29 1999-08-05 Sepracor Inc. Methods and compositions for aiding in smoking cessation and for treating pain and other disorders using optically pure (-)-bupropion
EP1051167A1 (en) 1998-01-29 2000-11-15 Sepracor, Inc. Pharmaceutical uses of optically pure (-) -bupropion
WO1999038502A1 (en) * 1998-01-29 1999-08-05 Sepracor Inc. Pharmaceutical uses of optically pure (+)-bupropion
US6150420A (en) * 1998-06-01 2000-11-21 Theramax, Inc. Method for enhanced brain delivery of bupropion
US6153223A (en) * 1998-06-05 2000-11-28 Watson Pharmaceuticals, Inc. Stabilized pharmaceutical compositions
US6096341A (en) * 1998-10-30 2000-08-01 Pharma Pass Llc Delayed release tablet of bupropion hydrochloride
US6033686A (en) * 1998-10-30 2000-03-07 Pharma Pass Llc Controlled release tablet of bupropion hydrochloride
US6238697B1 (en) * 1998-12-21 2001-05-29 Pharmalogix, Inc. Methods and formulations for making bupropion hydrochloride tablets using direct compression
US6855820B2 (en) * 1999-01-20 2005-02-15 Smithkline Beecham Corporation Pharmaceutically active morpholinol
US6734213B2 (en) 1999-01-20 2004-05-11 Smithkline Beecham Corporation Pharmaceutically active morpholinol
US6589553B2 (en) * 2001-02-08 2003-07-08 Andrx Pharmaceuticals, Inc. Controlled release oral dosage form
US8545880B2 (en) * 1999-02-26 2013-10-01 Andrx Pharmaceuticals, Llc Controlled release oral dosage form
US6337328B1 (en) * 1999-03-01 2002-01-08 Sepracor, Inc. Bupropion metabolites and methods of use
US6342496B1 (en) 1999-03-01 2002-01-29 Sepracor Inc. Bupropion metabolites and methods of use
USD430285S (en) * 1999-04-16 2000-08-29 Merck & Co., Inc. Tablet
US6280763B1 (en) 1999-05-10 2001-08-28 Pierce Management, Llc Apparatus and method for transdermal delivery of bupropion
HK1050135A1 (zh) * 1999-11-02 2003-06-13 Depomed, Inc. 用於促进将药物给予胃的饭後模式药理学诱导
US6306436B1 (en) 2000-04-28 2001-10-23 Teva Pharmaceuticals Usa, Inc. Stabilized, acid-free formulation for sustained release of bupropion hydrochloride
CA2796884A1 (en) * 2001-02-08 2002-08-15 Andrx Pharmaceuticals, Inc. Improved controlled release oral dosage form
ITMI20011457A1 (it) * 2001-07-09 2003-01-09 Valpharma Sa Composizione farmaceutica a rilascio modificato contenente bupropionehc1 come sostanza attiva
US20030044462A1 (en) * 2001-08-20 2003-03-06 Kali Laboratories, Inc. Sustained release tablets containing bupropion hydrochloride
AU2003217676B2 (en) 2002-02-22 2009-06-11 Takeda Pharmaceutical Company Limited Active agent delivery systems and methods for protecting and administering active agents
KR101072885B1 (ko) * 2002-05-17 2011-10-17 듀크 유니버시티 비만치료방법
US20050215552A1 (en) * 2002-05-17 2005-09-29 Gadde Kishore M Method for treating obesity
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
JP2006507298A (ja) * 2002-10-30 2006-03-02 ファルマシア コーポレーション 経口持続放出型錠剤、ならびにその製造法および使用法
US20040096497A1 (en) * 2002-11-19 2004-05-20 Ponder Garratt W. Methods of providing controlled-release pharmaceutical compositions and controlled-release pharmaceutical compositions
US6893660B2 (en) * 2002-11-21 2005-05-17 Andrx Pharmaceuticals, Inc. Stable pharmaceutical compositions without a stabilizer
PL1617832T3 (pl) * 2003-04-29 2009-01-30 Orexigen Therapeutics Inc Kompozycje wpływające na utratę wagi
DE102004032051A1 (de) * 2004-07-01 2006-01-19 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform
US20070048228A1 (en) * 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
US8075872B2 (en) 2003-08-06 2011-12-13 Gruenenthal Gmbh Abuse-proofed dosage form
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
CN1819821B (zh) * 2003-08-08 2010-10-13 拜奥维尔实验室国际股份有限公司 盐酸安非他酮的改良释放片剂
WO2005070461A2 (en) 2004-01-13 2005-08-04 Duke University Compositions of an anticonvulsant and an antipsychotic drug for affecting weight loss
US20060160750A1 (en) * 2004-01-13 2006-07-20 Krishnan K R R Compositions of an anticonvulsant and an antipsychotic drug and methods of using the same for affecting weight loss
US7713959B2 (en) * 2004-01-13 2010-05-11 Duke University Compositions of an anticonvulsant and mirtazapine to prevent weight gain
US20060100205A1 (en) * 2004-04-21 2006-05-11 Eckard Weber Compositions for affecting weight loss
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
USD515202S1 (en) 2004-07-19 2006-02-14 Merck & Co., Inc Tablet
US8586085B2 (en) 2004-11-08 2013-11-19 Biokey, Inc. Methods and formulations for making pharmaceutical compositions containing bupropion
US20060099262A1 (en) * 2004-11-08 2006-05-11 Biokey, Inc. Methods and formulations for making controlled release oral dosage form
GB0425445D0 (en) * 2004-11-18 2004-12-22 Smithkline Beecham Corp Novel compositions
KR100670798B1 (ko) 2004-12-17 2007-01-17 한국전자통신연구원 데이터베이스 캐시 시스템
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
EP2474308A1 (en) 2005-06-27 2012-07-11 Valeant International (Barbados) SRL Pharmaceutical formulations containing bupropion hydrobromide
EA200801080A1 (ru) * 2005-10-14 2009-02-27 Х. Лундбекк А/С Стабильные фармацевтические лекарственные формы, содержащие эсциталопрам и бупропион
WO2007053796A2 (en) * 2005-10-14 2007-05-10 Forest Laboratories, Inc. Methods of treating central nervous system disorders with a low dose combination of escitalopram and bupropion
EP1951212A2 (en) 2005-11-22 2008-08-06 Orexigen Therapeutics, Inc. Compositions and methods for increasing insulin sensitivity
ATE547097T1 (de) * 2005-11-28 2012-03-15 Orexigen Therapeutics Inc Zonisamid-formulierung mit verzögerter freisetzung
EP1999303A4 (en) * 2006-02-27 2010-09-08 Univ Leland Stanford Junior METHOD FOR IDENTIFYING UPR INHIBITORS
US20090181098A1 (en) 2006-03-07 2009-07-16 Osteoscreen Ip, Llc Hmg-Co-a Reductase Inhibitor Enhancement of Bone and Cartilage
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
CN101808634A (zh) 2006-06-13 2010-08-18 利兰·斯坦福青年大学托管委员会 半胱氨酸蛋白酶的环氧化物抑制剂
US8703191B2 (en) * 2006-07-25 2014-04-22 Intelgenx Corp. Controlled-release pharmaceutical tablets
US7674479B2 (en) * 2006-07-25 2010-03-09 Intelgenx Corp. Sustained-release bupropion and bupropion/mecamylamine tablets
US20100008987A1 (en) * 2006-08-21 2010-01-14 Pasula Basavaiah Chowdary Modified Release Pharmaceutical Composition of Bupropion Hydrochloride
KR20190042766A (ko) 2006-11-09 2019-04-24 오렉시젠 세러퓨틱스 인크. 신속하게 용해되는 중간층을 포함하는 층상의 약제학적 제형
KR20090090316A (ko) 2006-11-09 2009-08-25 오렉시젠 세러퓨틱스 인크. 체중 감량 약물을 투여하기 위한 단위 용량 팩키지 및 투여 방법
DE102007011485A1 (de) 2007-03-07 2008-09-11 Grünenthal GmbH Darreichungsform mit erschwertem Missbrauch
EP2142183A2 (en) 2007-04-09 2010-01-13 Sepracor Inc. Methods and compositions comprising desvenlafaxine or duloxetine for treating sleep-related breathing disorders
JP2010530422A (ja) * 2007-06-18 2010-09-09 ザ ジェネラル ホスピタル コーポレイション うつ病のための組合せ治療
US20090162434A1 (en) * 2007-12-21 2009-06-25 Disphar International Bv Mesalazine tablet
JP5774853B2 (ja) 2008-01-25 2015-09-09 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 医薬投薬形
US9339500B2 (en) 2008-03-04 2016-05-17 Intra-Cellular Therapies, Inc. Methods of treating vasomotor symptoms
DK2273983T3 (en) 2008-05-09 2016-09-19 Gruenenthal Gmbh A process for the preparation of a powdery formulation intermediate and a fixed final dosage form using a sprøjtestørkningstrin
JP2011521973A (ja) 2008-05-30 2011-07-28 オレキシジェン・セラピューティクス・インコーポレーテッド 内臓脂肪の状態を処置するための方法
TW201039815A (en) 2009-04-13 2010-11-16 Resolvyx Pharmaceuticals Inc Compositions and methods for the treatment of inflammation
TW201105316A (en) * 2009-07-22 2011-02-16 Gruenenthal Gmbh Hot-melt extruded pharmaceutical dosage form
RU2015138422A (ru) 2009-07-22 2018-12-25 Грюненталь Гмбх Стабильная при окислении, прочная на излом лекарственная форма
US20110136815A1 (en) * 2009-12-08 2011-06-09 Horst Zerbe Solid oral film dosage forms and methods for making same
US10610528B2 (en) 2009-12-08 2020-04-07 Intelgenx Corp. Solid oral film dosage forms and methods for making same
CN102724878A (zh) 2010-01-11 2012-10-10 奥雷西根治疗公司 在重度抑郁症患者中提供体重减轻疗法的方法
US9579285B2 (en) 2010-02-03 2017-02-28 Gruenenthal Gmbh Preparation of a powdery pharmaceutical composition by means of an extruder
JP5925779B2 (ja) 2010-09-02 2016-05-25 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 無機塩を含む不正使用抵抗性剤形
MX2013002293A (es) 2010-09-02 2013-05-09 Gruenenthal Gmbh Forma de dosificacion resistente a alteracion que comprende un polimero anionico.
CN103327972A (zh) 2010-10-11 2013-09-25 里兰斯坦福初级大学理事会 取代的苯甲酰胺及其用途
WO2012058065A1 (en) 2010-10-26 2012-05-03 Mars Incorporated Boronates as arginase inhibitors
WO2013017242A1 (en) 2011-07-29 2013-02-07 Grünenthal GmbH Tamper-resistant tablet providing immediate drug release
CN103841964A (zh) 2011-07-29 2014-06-04 格吕伦塔尔有限公司 提供药物立即释放的抗破碎片剂
PL2782570T3 (pl) 2011-11-21 2020-04-30 Calithera Biosciences Inc. Heterocykliczne inhibitory glutaminazy
JP6117249B2 (ja) 2012-02-28 2017-04-19 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 薬理学的に活性な化合物および陰イオン性ポリマーを含むタンパーレジスタント剤形
SG10201509063SA (en) 2012-04-12 2015-12-30 Univ Leland Stanford Junior Substituted benzamides and their uses
WO2013156453A1 (en) 2012-04-18 2013-10-24 Grünenthal GmbH Tamper resistant and dose-dumping resistant pharmaceutical dosage form
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
PL3730132T3 (pl) 2012-06-06 2022-10-10 Nalpropion Pharmaceuticals Llc Kompozycja do zastosowania w sposobie leczenia nadwagi i otyłości u pacjentów z wysokim ryzykiem sercowo-naczyniowym
KR102220175B1 (ko) 2012-11-16 2021-02-24 칼리테라 바이오사이언시즈, 인코포레이티드 헤테로사이클릭 글루타미나아제 억제제
KR102279618B1 (ko) 2013-03-15 2021-07-20 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 활성 기반 프로브 화합물, 조성물, 및 사용 방법
BR112015026549A2 (pt) 2013-05-29 2017-07-25 Gruenenthal Gmbh forma de dosagem à prova de violação contendo uma ou mais partículas
MX2015016254A (es) 2013-05-29 2016-04-20 Gruenenthal Gmbh Forma de dosificacion resistente al uso indebido con perfil de liberacion bimodal.
CA2917136C (en) 2013-07-12 2022-05-31 Grunenthal Gmbh Tamper-resistant dosage form containing ethylene-vinyl acetate polymer
CN105934241B (zh) 2013-11-26 2020-06-05 格吕伦塔尔有限公司 通过低温研磨制备粉末状药物组合物
US20150320690A1 (en) 2014-05-12 2015-11-12 Grünenthal GmbH Tamper resistant immediate release capsule formulation comprising tapentadol
US9872835B2 (en) 2014-05-26 2018-01-23 Grünenthal GmbH Multiparticles safeguarded against ethanolic dose-dumping
AU2015274361B2 (en) 2014-06-13 2020-11-05 Calithera Biosciences, Inc. Combination therapy with glutaminase inhibitors
WO2016022969A1 (en) 2014-08-07 2016-02-11 Calithera Biosciences, Inc. Crystal forms of glutaminase inhibitors
ES2901418T3 (es) 2014-08-13 2022-03-22 Eolas Therapeutics Inc Difluoropirrolidinas como moduladores del receptor de orexina
EP3212195A4 (en) 2014-10-31 2018-06-06 The Regents of The University of California Compositions and methods for treating hiv-associated cognitive dysfunction
CN114159430B (zh) 2015-03-10 2024-10-25 奥瑞基尼探索技术有限公司 作为免疫调节剂的1,2,4-噁二唑和噻二唑化合物
MX2017013637A (es) 2015-04-24 2018-03-08 Gruenenthal Gmbh Forma de dosificacion resistente a alteraciones con liberacion inmediata y resistencia contra la extraccion por solventes.
CN107921051A (zh) 2015-06-23 2018-04-17 卡里塞拉生物科学股份公司 抑制精氨酸酶活性的组合物和方法
US10016471B2 (en) 2015-06-29 2018-07-10 Phloronol, Inc. Solid pharmaceutical compositions of brown algae
EP3346991A1 (en) 2015-09-10 2018-07-18 Grünenthal GmbH Protecting oral overdose with abuse deterrent immediate release formulations
GB2542881B (en) 2015-10-02 2020-01-01 Carr Andrew Crystal forms of ß-nicotinamide mononucleotide
US10258619B2 (en) 2015-10-05 2019-04-16 Calithera Biosciences, Inc. Combination therapy with glutaminase inhibitors and immuno-oncology agents
KR20220118559A (ko) 2015-10-30 2022-08-25 칼리테라 바이오사이언시즈, 인코포레이티드 아르기닌 활성 억제용 조성물 및 방법
EP3377512A4 (en) 2015-11-16 2019-09-18 Ichorion Therapeutics, Inc. Nucleic Acid PRODRUGS
DK3414241T3 (da) 2016-02-12 2022-08-01 Astrazeneca Ab Halogensubstituerede piperidiner som orexinreceptormodulatorer
AU2017250300B2 (en) 2016-04-14 2023-04-06 Massachusetts Institute Of Technology Porous silicon materials comprising a metal silicate for delivery of therapeutic agents
CN113730421A (zh) 2016-04-22 2021-12-03 维京治疗股份有限公司 甲状腺β-激动剂的应用
US10793590B2 (en) 2016-06-03 2020-10-06 President And Fellows Of Harvard College Antifungal compounds
EP3503904B1 (en) 2016-08-25 2026-01-21 California Institute of Technology Ascaroside treatment of eosinophilic esophagitis
WO2018039612A1 (en) 2016-08-26 2018-03-01 The Regents Of The University Of California Compositions and methods for promoting hair growth with mpc1 inhibitors
CN109906082A (zh) 2016-09-07 2019-06-18 塔夫茨大学信托人 使用免疫dash抑制剂和pge2拮抗剂的组合治疗
EP3510040A4 (en) 2016-09-09 2020-06-03 Calithera Biosciences, Inc. EKTONUCLEOTIDASE INHIBITORS AND METHOD FOR USE THEREOF
EP3509583B1 (en) 2016-09-09 2021-06-30 The Regents of the University of California Estrogen receptor ligands, compositions and methods related thereto
US12129248B2 (en) 2016-09-26 2024-10-29 Dana-Farber Cancer Institute, Inc. Chromobox protein inhibitors and uses thereof
US11510931B2 (en) 2016-09-28 2022-11-29 Medicon Pharmaceuticals, Inc. Compositions and methods for treating ophthalmic conditions
EP3519050B1 (en) 2016-09-28 2023-06-07 Medicon Pharmaceuticals, Inc. Compositions for treating ophthalmic conditions
US11291674B2 (en) 2016-11-08 2022-04-05 Calithera Biosciences, Inc. Arginase inhibitor combination therapies
WO2018098376A1 (en) 2016-11-22 2018-05-31 Elektrofi, Inc. Particles comprising a therapeutic or diagnostic agent and suspensions and methods of use thereof
AU2017382405B2 (en) 2016-12-22 2021-12-16 Calithera Biosciences, Inc. Compositions and methods for inhibiting arginase activity
WO2018119476A1 (en) 2016-12-23 2018-06-28 The Board Of Trustees Of The Leland Stanford Junior University Activity-based probe compounds, compositions, and methods of use
JP2020511424A (ja) 2017-01-18 2020-04-16 ヴァンダービルト ユニバーシティーＶａｎｄｅｒｂｉｌｔ Ｕｎｉｖｅｒｓｉｔｙ 選択的ｂｍｐ阻害としての縮合複素環式化合物
JP7146785B2 (ja) 2017-02-24 2022-10-04 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング ジヒドロオロテートオキシゲナーゼ阻害剤としての１、４、６－トリ置換－２－アルキル－１Ｈ－ベンゾ［ｄ］イミダゾール誘導体
HUE062648T2 (hu) 2017-03-31 2023-11-28 Aurigene Oncology Ltd Vegyületek és készítmények hematológiai rendellenességek kezelésére
WO2018209288A1 (en) 2017-05-12 2018-11-15 Massachusetts Institute Of Technology Argonaute protein-double stranded rna complexes and uses related thereto
US11325943B2 (en) 2017-06-02 2022-05-10 Stealth Biotherapeutics Inc. Crystalline salt forms of SBT-20
CN116120314A (zh) 2017-06-30 2023-05-16 加利福尼亚大学董事会 用于调节毛发生长的组合物和方法
US10526334B2 (en) 2017-07-19 2020-01-07 California Institute Of Technology Methods for preparing bis-tetrahydroisoquinoline-containing compounds
EP3658612A4 (en) 2017-07-25 2021-06-02 Elektrofi, Inc. FORMATION OF PARTICLES WITH SUBSTANCES
US20200290978A1 (en) 2017-09-26 2020-09-17 The Regents Of The University Of California Compositions and methods for treating cancer
US11530209B2 (en) 2017-10-04 2022-12-20 Dana-Farber Cancer Institute, Inc. Small molecule inhibition of transcription factor SALL4 and uses thereof
JP7618445B2 (ja) 2017-10-11 2025-01-21 オーリジーン オンコロジー リミテッド ３－置換１，２，４－オキサジアゾールの結晶形態
MY203827A (en) 2017-10-31 2024-07-19 Curis Inc Compounds and compositions for treating hematological disorders
MY206121A (en) 2017-11-03 2024-11-29 Aurigene Discovery Tech Ltd Dual inhibitors of tim-3 and pd-1 pathways
AU2018360389B2 (en) 2017-11-06 2024-09-19 Aurigene Oncology Limited Conjoint therapies for immunomodulation
TW201938159A (zh) 2017-12-22 2019-10-01 英商梅迪繆思有限公司 Keap1之btb域之小分子調節劑
EP3749640B1 (en) 2018-01-30 2025-07-16 The Regents of the University of California Inhibitors of the wnt/beta-catenin pathway
EP3765460A1 (en) 2018-03-14 2021-01-20 Vanderbilt University Inhibition of bmp signaling, compounds, compositions and uses thereof
EP3768259A4 (en) 2018-03-14 2022-04-06 Aurigene Discovery Technologies Limited METHOD FOR MODULATING TIGIT AND PD-1 SIGNALING PATHWAYS USING 1,2,4-OXADIAZOLE COMPOUNDS
JP2021521280A (ja) 2018-04-12 2021-08-26 マトルクス セラピューティクス コーポレーション 弾性線維分解を治療するための組成物及び方法
WO2019217450A1 (en) 2018-05-08 2019-11-14 Rhode Island Hospital Anti-chi3l1 antibodies for the detection and/or treatment of nonalcoholic fattly liver disease/nonalcoholic steatohepatitis and subsequent complications
EP3796913A4 (en) 2018-05-11 2022-03-02 Rhode Island Hospital COMPOSITIONS AND METHODS FOR THE TREATMENT OF JOINT DISEASES WITH REVERSE TRANSCRIPTASE NUCLEOSIDE INHIBITORS
US12115262B2 (en) 2018-05-24 2024-10-15 Elektrofi, Inc. Particles comprising a therapeutic or diagnostic agent and suspensions and methods of use thereof
US20210122771A1 (en) 2018-06-29 2021-04-29 The Regents Of The University Of California New molecular tweezers against neurological disorders and viral infections
CA3107750A1 (en) 2018-07-27 2020-01-30 California Institute Of Technology Cdk inhibitors and uses thereof
KR20210071974A (ko) 2018-09-05 2021-06-16 더 제너럴 하스피탈 코포레이션 사이토카인 방출 증후군을 치료하는 방법
WO2020056109A1 (en) 2018-09-12 2020-03-19 The Board Of Regents Of The University Of Oklahoma Combination cancer therapies
EP3867223B1 (en) 2018-10-17 2025-12-10 The Regents of the University of California Prodrugs of alpha-ketoglutarate, alpha-ketobutyrate, alpha-ketoisovalerate, and alpha-ketoisohexanoate, and uses thereof
WO2020086963A1 (en) 2018-10-26 2020-04-30 Keros Therapeutics Crystal forms of an alk2 inhibitor
KR20210068591A (ko) 2018-10-31 2021-06-09 주식회사 인투셀 융합된 헤테로시클릭 벤조디아제핀 유도체 및 그의 용도
AU2020209215B2 (en) 2019-01-18 2023-02-02 Astrazeneca Ab PCSK9 inhibitors and methods of use thereof
EP3911640A4 (en) 2019-01-18 2022-10-26 Astrazeneca AB PCSK9 INHIBITORS AND METHODS OF USE THEREOF
KR20210137434A (ko) 2019-01-25 2021-11-17 브라운 유니버시티 연령 관련 염증 및 장애를 치료, 예방 또는 역전시키기 위한 조성물 및 방법
WO2020160323A2 (en) 2019-01-31 2020-08-06 Elektrofi, Inc. Particle formation and morphology
CA3131753A1 (en) 2019-03-14 2020-09-17 Astrazeneca Ab Lanabecestat for weight loss
JP6890865B1 (ja) 2019-06-03 2021-06-18 株式会社大分大学先端医学研究所 狂犬病治療のための環状アミド化合物およびその方法
CN114514035A (zh) 2019-09-13 2022-05-17 伊勒卓菲公司 递送用于治疗疾病的治疗性生物制剂的组合物和方法
EP4058434A1 (en) 2019-11-12 2022-09-21 Genzyme Corporation 6-membered heteroarylaminosulfonamides for treating diseases and conditions mediated by deficient cftr activity
WO2021113806A1 (en) 2019-12-05 2021-06-10 Genzyme Corporation Arylamides and methods of use thereof
WO2021113809A1 (en) 2019-12-05 2021-06-10 Genzyme Corporation Arylamides and methods of use thereof
KR20210076875A (ko) 2019-12-16 2021-06-24 주식회사 스마틴바이오 신생혈관형성인자의 억제를 위한 화합물 및 그 용도
WO2021142221A1 (en) 2020-01-10 2021-07-15 The Regents Of The University Of California Compositions and methods for the treatment of neurodegenerative diseases
US20230094393A1 (en) 2020-02-07 2023-03-30 Elektrofi, Inc. Peptide particles and methods of formation
WO2021168271A1 (en) 2020-02-19 2021-08-26 Elektrofi, Inc. Droplet formation and particle morphology
WO2021207135A1 (en) 2020-04-06 2021-10-14 The Regents Of The University Of California Compounds and methods for inducing ucp1 expression
WO2021212019A1 (en) 2020-04-17 2021-10-21 Elektrofi, Inc. Methods of forming particles by continuous droplet formation and dehydration
KR102698413B1 (ko) 2020-05-05 2024-08-26 뉴베일런트, 아이엔씨. 헤테로방향족 거대환식 에터 화학치료제
CA3179700A1 (en) 2020-05-05 2021-11-11 Nuvalent, Inc. Heteroaromatic macrocyclic ether chemotherapeutic agents
WO2021263072A1 (en) 2020-06-25 2021-12-30 Dana-Farber Cancer Institute, Inc. Methods of treating disease
CN111830151B (zh) * 2020-07-01 2021-05-04 迪沙药业集团有限公司 盐酸安非他酮组合物质量控制用系统适用性对照品
CA3191166A1 (en) 2020-08-10 2022-02-17 Dana-Farber Cancer Institute, Inc. Substituted 3-amino-4-methylbenzenesulfonamides as small molecule inhibitors of ubiquitin-specific protease 28
CA3191163A1 (en) 2020-08-10 2022-02-17 Dana-Farber Cancer Institute, Inc. Fused tricyclic pyrimidine-thieno-pyridine small molecule inhibitors of ubiquitin-specific protease 28
CA3191164A1 (en) 2020-08-10 2022-02-17 Dana-Farber Cancer Institute, Inc. Substituted 1,2,4-oxadiazoles as small molecule inhibitors of ubiquitin-specific protease 28
CN116323571A (zh) 2020-10-23 2023-06-23 丹娜法伯癌症研究院 肌酸激酶（ck）的共价抑制剂以及其用于治疗和预防癌症的用途
WO2022133237A2 (en) 2020-12-18 2022-06-23 Cornell University Methods of treating neurodegenerative disorders and stat3-linked cancers using suppressors of electron leak
IL303813A (en) 2020-12-21 2023-08-01 Univ Cornell Peptide-linked drug delivery system
US20240132480A1 (en) 2021-01-08 2024-04-25 Cornell University Inhibitors of mycobacterium tuberculosis lipoamide dehydrogenase
PE20240327A1 (es) 2021-04-13 2024-02-22 Nuvalent Inc Heterociclos con sustitucion amino para tratar canceres con mutaciones de egfr
IL311038A (en) 2021-09-03 2024-04-01 Genzyme Corp Indole compounds and methods of use
WO2023034946A1 (en) 2021-09-03 2023-03-09 Genzyme Corporation Indole compounds and uses thereof in the treatement of cystic fibrosis
MX2024003738A (es) 2021-10-01 2024-06-19 Nuvalent Inc Formas solidas, composiciones farmaceuticas y preparacion de compuestos de eter macrociclico heteroaromatico.
MX2024003439A (es) 2021-10-01 2024-06-21 Nuvalent Inc Métodos para tratar tumores sólidos usando compuestos de éter macrocíclico heteroaromático.
US20250213652A1 (en) 2022-03-31 2025-07-03 Revolo Biotherapeutics Limited Compositions and their use in methods for treating intestinal inflammation
IL315589A (en) 2022-04-07 2024-11-01 Nuvalent Inc Solid tumor treatment methods using (19R)-5-chloro-3-ethyl-16-fluoro-10,19-dimethyl-20-oxa-3,4,10,11,23-pentazapentacyclo[19.3.1.02,6.08,12.013 18]pentacose-1(24),2(6),4,8,11,13,15,17,21(25),22-decayin-22-amine
TW202400608A (zh) 2022-04-07 2024-01-01 美商努法倫特公司 雜芳族巨環醚化合物之固體形式、醫藥組合物及製備
KR20250029029A (ko) 2022-04-29 2025-03-04 일렉트로피, 아이엔씨. 주사가능한 현탁액
JP2025521110A (ja) 2022-05-16 2025-07-08 レボロ バイオセラピューティクス リミテッド 食物アレルギーを予防または治療するための方法および組成物
WO2023250157A1 (en) 2022-06-24 2023-12-28 Cornell University Inhibitors of mycobacterium tuberculosis lipoamide dehydrogenase
CN118785900A (zh) * 2022-06-30 2024-10-15 艾克萨姆治疗公司 包含安非他酮和半胱氨酸的药物组合物
US12156914B2 (en) 2022-06-30 2024-12-03 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising bupropion and cysteine
WO2024013209A1 (en) 2022-07-13 2024-01-18 Astrazeneca Ab Pcsk9 inhibitors and methods of use thereof
KR20250044905A (ko) 2022-08-04 2025-04-01 다이이치 고교 세이야쿠 가부시키가이샤 고리형 펩티드 유도체와 그 제조 방법 및 조성물
WO2024036097A1 (en) 2022-08-12 2024-02-15 Nuvalent, Inc. Heteroaromatic macrocyclic ether compounds and isotopologues thereof
EP4568969A1 (en) 2022-08-12 2025-06-18 Nuvalent, Inc. Heteroaromatic macrocyclic ether compounds
EP4593814A1 (en) 2022-09-26 2025-08-06 Rose Research Center, LLC Combination for use in a method of preventing weight gain
WO2024071371A1 (ja) 2022-09-30 2024-04-04 ユビエンス株式会社 複素環式化合物
CN119947740A (zh) 2022-09-30 2025-05-06 第一工业制药株式会社 用于处置或预防眼科疾病的环状肽衍生物组合物
IL319638A (en) 2022-10-19 2025-05-01 Nuvalent Inc Chemotherapeutic agents of heteroaromatic macrocyclic esters
IL320605A (en) 2022-11-04 2025-07-01 Dks Co Ltd Cyclic peptide derivative compound for the treatment or prevention of neuropathic pain and/or inflammatory pain
IL320606A (en) 2022-11-04 2025-07-01 Dks Co Ltd Cyclic peptide derivative composition for treating or preventing central nervous system injury/disease
AU2024258768A1 (en) 2023-04-18 2025-12-04 Revolo Biotherapeutics Limited Methods and compositions for preventing or treating eosinophilic esophagitis
WO2024233456A1 (en) 2023-05-05 2024-11-14 The Board Of Regents Of The University Of Oklahoma Variants of adrenomedullin (am) and adrenomedullin 2/intermedin (am2/imd) and methods of use
WO2025037259A1 (en) 2023-08-15 2025-02-20 Revolo Biotherapeutics Limited Methods and compositions for preventing or treating severe asthma
WO2025042868A1 (en) 2023-08-23 2025-02-27 The Board Of Regents Of The University Of Oklahoma Combinations of heteroarotinoids and glycolytic inhibitors for use as cancer treatments
US20250268826A1 (en) 2023-09-18 2025-08-28 Flagship Pioneering Innovations Vii, Llc Ionizable lipidoid compositions and therapeutic uses thereof
WO2025072120A1 (en) 2023-09-25 2025-04-03 Nuvalent, Inc. Heteroaromatic macrocyclic ether compounds
WO2025072117A1 (en) 2023-09-25 2025-04-03 Nuvalent, Inc. Heteroaromatic macrocyclic ether compounds and isotopologues thereof
WO2025085360A1 (en) 2023-10-16 2025-04-24 The Board Of Regents Of The University Of Oklahoma Heteroarotinoids and/or cdk4/6 inhibitors for treating human papillomavirus (hpv)-induced dysplasias, warts, and cancer in hpv-infected subjects
US20250135196A1 (en) 2023-10-27 2025-05-01 Brown University Compositions, systems, and methods for treating cancer using tumor treating fields with inhibitors of mif, mica, and/or micb
US20250162981A1 (en) 2023-11-14 2025-05-22 Flagship Pioneering Innovations Vii, Llc Ionizable lipidoid compositions and therapeutic uses thereof
WO2025212478A1 (en) 2024-04-01 2025-10-09 Nuvalent, Inc. Methods of treating solid tumor using heteroaromatic macrocyclic ether compounds
WO2025235874A1 (en) 2024-05-10 2025-11-13 Schrödinger, Inc. Heterocyclics as egfr inhibitors
WO2025235872A1 (en) 2024-05-10 2025-11-13 Schrödinger, Inc. Heterocyclics as egfr inhibitors
US20250383333A1 (en) 2024-06-12 2025-12-18 Elektrofi, Inc. Determination of particulate contaminants in particles and compositions

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE759838A (fr) * 1969-12-04 1971-06-03 Wellcome Found Cetones a activite biologique
US3885046A (en) * 1969-12-04 1975-05-20 Burroughs Wellcome Co Meta chloro or fluoro substituted alpha-T-butylaminopropionphenones in the treatment of depression
CA948388A (en) * 1970-02-27 1974-06-04 Paul B. Hansen Pattern bonded continuous filament web
US4347257A (en) * 1979-10-09 1982-08-31 Burroughs Wellcome Co. Prolactin suppression in mammals
NL8100259A (nl) * 1980-01-21 1981-08-17 Wellcome Found Combinaties van ketonen met heterocyclische verbindingen, famaceutische preparaten welke deze bevatten, werkwijze om dergelijke preparaten te bereiden en toepassing daarvan in de geneeskunde.
US4355179A (en) * 1980-04-14 1982-10-19 Burroughs Wellcome Co. Radioactive nuclide labeled propiophenone compounds
US4356165A (en) * 1980-04-14 1982-10-26 Burroughs Wellcome Co. Bupropion radioimmunoassay, and kit
US4347382A (en) * 1980-04-15 1982-08-31 Burroughs Wellcome Co. 3H Labeled compounds
US4347178A (en) * 1980-04-14 1982-08-31 Burroughs Wellcome Co. Compounds and methods of making
US4347176A (en) * 1980-04-14 1982-08-31 Burroughs Wellcome Co. Compounds and methods of making same
US4347177A (en) * 1980-04-14 1982-08-31 Burroughs Wellcome Co. Compounds and methods of making them
US4435449A (en) * 1981-05-14 1984-03-06 Burroughs Wellcome Co. Treatment of minimal brain dysfunction (MBD)
US4425363A (en) * 1981-05-14 1984-01-10 Burroughs Wellcome Co. Treatment of tardive dyskinesia in mammals
US4393078A (en) * 1982-03-15 1983-07-12 Burroughs Wellcome Co. Bupropion and ethanol
US4438138A (en) * 1982-12-06 1984-03-20 Burroughs Wellcome Co. Reduction of cholesterol with meta-chloro α-t-butylaminopropiophenone
GB8322007D0 (en) * 1983-08-16 1983-09-21 Wellcome Found Pharmaceutical delivery system
USRE33994E (en) * 1983-08-16 1992-07-14 Burroughs Wellcome Co. Pharmaceutical delivery system
EP0171457B1 (en) * 1984-08-17 1992-03-25 The Wellcome Foundation Limited Composition for the controlled discharge of an active ingredient, and its preparation
US4507323A (en) * 1984-07-25 1985-03-26 Burroughs Wellcome Co. Treatment of psychosexual dysfunctions
US4769027A (en) * 1984-08-15 1988-09-06 Burroughs Wellcome Co. Delivery system
AU657973B2 (en) * 1991-05-07 1995-03-30 Dynagen, Inc. A controlled, sustained release delivery system for smoking cessation

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001517625A (ja) * 1997-09-25 2001-10-09 バイエル・アクチエンゲゼルシヤフト 活性成分放出制御薬物製剤
JP2002537319A (ja) * 1999-02-26 2002-11-05 アンドルックス ファーマスーティカルズ インコーポレーテッド 放出制御されたブプロピオン製剤
JP2023516404A (ja) * 2020-03-05 2023-04-19 アッヴィ・インコーポレイテッド エラゴリクスの投与方法

Also Published As

Publication number Publication date
LU90656I2 (fr) 2001-01-15
DE69316015D1 (de) 1998-02-05
MX9304967A (es) 1994-05-31
GR3025794T3 (en) 1998-03-31
KR100294154B1 (ko) 2001-09-17
HK1004323A1 (en) 1998-11-20
AU4725893A (en) 1994-03-15
GB9217295D0 (en) 1992-09-30
EP0656775B1 (en) 1997-12-29
EP0656775A1 (en) 1995-06-14
CY2143B1 (en) 2002-06-21
ZA935942B (en) 1995-02-13
CA2142320C (en) 2001-10-09
TW260607B (OSRAM) 1995-10-21
ES2111168T3 (es) 1998-03-01
ATE161422T1 (de) 1998-01-15
AU677595B2 (en) 1997-05-01
SG43911A1 (en) 1997-11-14
CA2142320A1 (en) 1994-03-03
US5427798A (en) 1995-06-27
KR950702827A (ko) 1995-08-23
IL106693A (en) 1997-06-10
NZ254947A (en) 1996-04-26
DE69316015T2 (de) 1998-04-16
WO1994004138A1 (en) 1994-03-03
IL106693A0 (en) 1993-12-08

Similar Documents

Publication Publication Date Title
JPH08500110A (ja) ブプロピオン含有持続放出型錠剤
CA1313133C (en) Therapeutic agents
KR100391104B1 (ko) 생체 이용율이 높은 페노피브레이트 제약학적 조성물과 그의제조방법
US5811126A (en) Controlled release matrix for pharmaceuticals
AU639334B2 (en) Taste masking and sustained release coatings for pharmaceuticals
EP0218148B1 (en) Slow-release pharmaceutical composition
US5529783A (en) Rotor granulation and coating of acetaminophen, pseudoephedrine, chlorpheniramine, and, optionally dextromethorphan
AU2001260212C1 (en) Composition
AU4595593A (en) Controlled release morphine preparation
AU2002249881A1 (en) Sustained release pharmaceutical dosage forms with minimized PH dependent dissolution profiles
SE453797B (sv) Terapeutisk, solid enhetsdoseringsform med forlengt utlosningsmonster vars berarmaterial innehaller hydroxypropylmetylcellulosa med hog molekyler vikt
KR20050083816A (ko) 24시간 효능의 서방 트라마돌 조성물
WO2002058676A1 (en) Sustained release pharmaceutical dosage forms with minimized ph dependent dissolution profiles
JP5420590B2 (ja) ｐＨ非依存延長放出性医薬組成物
US20160256398A1 (en) Compositions of 1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]piperazine
CN101006985A (zh) 药用组合物
JPH0757726B2 (ja) 高分子量ヒドロキシプロピルメチルセルロースを基剤にした徐放性錠剤
WO2004078111A2 (en) Extended release minocycline compositions and processes for their preparation
US4940580A (en) Sustained release labetalol tablets
AU709413B2 (en) Sustained-release drug delivery employing a powdered hydrocolloid gum obtainable from higher plants
EP0266707A2 (en) Sustained release labetalol tablet
JPS6024766B2 (ja) 徐放性抗生物質錠
Ostwal et al. Development and evaluation for tablet-in capsule of nefedipine and atenolol
HK1004323B (en) Sustained release tablets containing bupropion
Bryan Jr Calcium diluents as matrix forming agents in sustained release dosage forms

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20040302

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20040527

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20040712

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20040902

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20050809

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060203

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20060207